Ashwagandha

Ashwagandha, an herb, has shown promise in alleviating menopausal symptoms due to its adaptogenic properties, which help balance hormones and reduce stress. Studies have shown its effectiveness in improving menopausal symptoms by regulating cortisol levels and promoting hormonal balance in women.

  • Brain Health

  • Libido

  • Energy

  • Relaxation

  • Sleep

Collapsible content

References

Modi MB, Donga SB, Dei L. Clinical evaluation of Ashokarishta, Ashwagandha Churna, and Praval Pishti in the management of menopausal syndrome. AYU. 2012;33(4):511-516. doi:10.4103/0974-8520.110529

Publication Date: "Oct–Dec 2012"

Peer Reviewed: Yes

Study Design: "randomized open clinical trial"

Methodology: 52 patients randomly selected, given ASK (25 ml twice daily with water after food), ASW (3 g twice daily with milk half an hour before food), and PP (1 capsule of 250 mg twice daily with milk half an hour before food) for 3 months, assessed with MRS and MENQOL.

Sample Size: "52 patients were registered in the study, out of which 51 patients completed the study."

Controls Used: None stated.

Dose Used: "ASK (25 ml twice daily with equal quantity of water, after food, orally), ASW (3 g twice daily with milk, half an hour before food, orally) and PP (1 capsule of 250 mg twice daily with milk, half an hour before food, orally) for 3 months."

Statistical Significance Declared: "Statistically highly significant (P < 0.01)" for relief in MRS symptoms and MENQOL improvement.

Adverse Events due to Ashwagandha Supplementation: "No any adverse effect was noted during the study."

Conflict of Interest: None stated


Gopal S, Ajgaonkar A, Kanchi P, Kaundinya A, Thakare V, Chauhan S, Langade D. Effect of an ashwagandha (Withania somnifera) root extract on climacteric symptoms in women during perimenopause: A randomized, double-blind, placebo-controlled study. J Obstet Gynaecol Res. Published online September 22, 2021. doi:10.1111/jog.15030

Publication Date: "First published: 22 September 2021"

Peer Reviewed: Yes

Study Design: "randomized, double-blind, placebo-controlled study"

Methodology: 8-week study, 100 women, randomized to placebo or 300 mg Ashwagandha root extract twice daily, outcomes measured using MRS, MENQoL, hot flash score, and hormonal changes in estradiol, FSH, LH, and testosterone.

Sample Size: "100 participants"

Controls Used: "placebo"

Dose Used: "300 mg of an Ashwagandha root extract twice daily"

Statistical Significance Declared: "Statistically significant reduction in total MRS score (p < 0.0001)", "Significant reductions in the psychological (p = 0.0003), somato-vegetative (p = 0.0152), and urogenital (p < 0.0001) domains", "Statistically significant reduction in total MENQoL scores (p < 0.0001)", "Statistically significant increase in serum estradiol (p < 0.0001)", "Significant reduction in serum FSH (p < 0.0001) and serum LH (p < 0.05)"

Adverse Events due to Ashwagandha Supplementation: "Three participants in the ashwagandha group reported abdominal discomfort, abdominal pain, and nausea", "adverse events reported were mild and temporary"

Conflict of Interest: "None declared"


Dongre S, Langade D, Bhattacharyya S. Efficacy and Safety of Ashwagandha (Withania somnifera) Root Extract in Improving Sexual Function in Women: A Pilot Study. BioMed Research International. 2015;2015(1):284154. doi:10.1155/2015/284154.

Publication Date: "First published: 04 October 2015"

Peer Reviewed: Yes

Study Design: "randomized, double blind, and placebo-controlled"

Methodology: 50 study subjects were randomized to either HCARE-treated group or placebo group, consumed either HCARE or placebo capsules of 300mg twice daily for 8 weeks, assessed using FSFI and FSDS, and the number of total and successful sexual encounters.

Sample Size: "50 study subjects", "n = 25" per group

Controls Used: "placebo- (starch-) treated group"

Dose Used: "300mg twice daily for 8 weeks"

Statistical Significance Declared: "p < 0.001 for FSFI Total score, FSFI domain score for 'arousal' (p < 0.001), 'lubrication' (p < 0.001), 'orgasm' (p = 0.004), and 'satisfaction' (p < 0.001), and also FSDS score (p < 0.001) and the number of successful sexual encounters (p < 0.001)"

Adverse Events due to Ashwagandha Supplementation: "No adverse effects of therapy were observed in the HCARE group."

Conflict of Interest: "There is no conflict of interests."


Raut AA, Rege NN, Tadvi FM, et al. Exploratory study to evaluate tolerability, safety, and activity of Ashwagandha (Withania somnifera) in healthy volunteers.J Ayurveda Integr Med. 2012;3(3):111-114. doi:10.4103/0975-9476.100168

Publication Date: "July-September 2012"

Peer Reviewed: Yes

Study Design: "prospective, open-labeled, variable doses in volunteers"

Methodology: Volunteers received WS capsules in escalating doses every 10 days for 30 days; assessments included symptoms/signs, vital functions, hematological and biochemical organ function tests, muscle activity, exercise tolerance, body fat percentage, and lean body weight.

Sample Size: "Eighteen apparently healthy volunteers (12M:6F, age:18-30 years, and BMI: 19-30)"

Controls Used: No control group used.

Dose Used: "750 mg/day x10 days, 1000 mg/day x 10 days, 1250 mg/day x 10 days"

Statistical Significance Declared: "Repeated measures ANOVA, McNemar's test, and paired t test were employed. P <0.05 was considered significant."

Adverse Events due to Ashwagandha Supplementation: "One volunteer showed increased appetite, libido, and hallucinogenic effects with vertigo at the lowest dose and was withdrawn from study."

Conflict of Interest: None declared


Dongre S, Langade D, Bhattacharyya S. Efficacy and safety of Ashwagandha (Withania somnifera) root extract in improving sexual function in women: a pilot study. BioMed Res Int. 2015;2015:284154. doi:10.1155/2015/284154

Publication Date: "04 October 2015"

Peer Reviewed: Yes

Study Design: "Double blind, placebo-controlled, randomized"

Methodology: 50 subjects randomized to HCARE-treated group or placebo-treated group, consumed 300mg capsules twice daily for 8 weeks, sexual function assessed using FSFI and FSDS scales, and number of total and successful sexual encounters recorded.

Sample Size: "50 study subjects" (25 in HCARE group, 25 in placebo group)

Controls Used: "Placebo- (starch-) treated group"

Dose Used: "300mg twice daily"

Statistical Significance Declared: "FSFI Total score (p < 0.001), FSFI domain score for 'arousal' (p < 0.001), 'lubrication' (p < 0.001), 'orgasm' (p = 0.004), and 'satisfaction' (p < 0.001), and also FSDS score (p < 0.001) and the number of successful sexual encounters (p < 0.001)"

Adverse Events due to Ashwagandha Supplementation: "No adverse effects of therapy were observed in the HCARE group."

Conflict of Interest: "There is no conflict of interests."


Mikulska P, Malinowska M, Ignacyk M, Szustowski P, Nowak J, Pesta K, Szeląg M, Szklanny D, Judasz E, Kaczmarek G, et al. Ashwagandha(Withania somnifera)—Current Research on the Health-Promoting Activities: A Narrative Review.Pharmaceutics. 2023; 15(4):1057. https://doi.org/10.3390/pharmaceutics15041057

Publication Date: "24 March 2023."

Peer Reviewed: Yes.

Study Design: "narrative review."

Methodology: Literature review of current research on Ashwagandha's effects.

Sample Size: Various sample sizes depending on individual studies reviewed.

Controls Used: Placebo groups in various studies.

Dose Used: Various, including "300 mg of Withania somnifera root extract twice daily for eight weeks."

Statistical Significance Declared: "Significantly greater increases in muscle strength and power" and "Significant improvement in maximal aerobic capacity, time to exhaustion, and ventilatory threshold."

Adverse Events due to Ashwagandha Supplementation: "Liver damage is usually cholestatic or mixed with severe jaundice and pruritus, but is self-limiting, with normalisation of liver test results within 1–5 months."

Conflict of Interest: "The authors declare no conflict of interest."


Kulkarni P, Khobragade P. Phytoestrogens Medicinal Herbs - Safe and Effective Alternative to Hormone Replacement Therapy in Menopausal Syndrome. J Res Tradit Med. 2016;2(5). doi:10.21276/jrtm.2016/278

Publication Date: "Received: 28/11/2016 Revised: 4/1/2016 Accepted: 16/1/2017"

Peer Reviewed: No

Study Design: "Review Article"

Methodology: "Literatures such as Brihattrayee (Three major compendia of Ayurved), Nighantu (Lexicon), modern textbooks written in 21 century, and journals from year 2000 upto 2016 were critically reviewed to explore safety and efficacy of phytoestrogens in Ayurvedic herbs."

Sample Size: Not applicable

Controls Used: Not applicable

Dose Used: Not applicable

Statistical Significance Declared: Not applicable

Adverse Events due to Ashwagandha Supplementation: None mentioned

Conflict of Interest: None mentioned


POTOCKA Z, BORYCKA A, JĘDRZEJEWSKA B, KOTULSKA M, LASKUS P, LICHMAN M, LUBCZYŃSKA Z, PRZERADZKI J, RZĄD K. Potential clinical usage of ashwagandha root extract: A review. J Educ Health Sport. 2023;29(1):35-44. doi:10.12775/JEHS.2023.29.01.004

Publication Date: "2023"

Peer Reviewed: Yes

Study Design: "Review"

Methodology: Literature review conducted using PubMed and Google Scholar online databases.

Sample Size: Small sample studies

Controls Used: Placebo group

Dose Used: Not specified

Statistical Significance Declared: "Not statistically significant improvement in quality of life compared to placebo group"

Adverse Events due to Ashwagandha Supplementation: None directly linked to Ashwagandha supplementation

Conflict of Interest: Not stated


Rawat N, Roushan R. Ashwagandha (Withania Somnifera); A potential aphrodisiac drug in Ayurveda. Int J Basic Appl Res. 2019;8:1034-1041.

Publication Date: "August 2018"

Peer Reviewed: Yes

Study Design: "randomized, and placebo-controlled study"

Methodology: Evaluated efficacy of Ashwagandha root extract in enhancing cardiorespiratory endurance and improving quality of life in healthy athletic adults.

Sample Size: "50 healthy male/female athletic adults."

Controls Used: "placebo"

Dose Used: Not specified in the provided text.

Statistical Significance Declared: "P< 0.05"

Adverse Events due to Ashwagandha Supplementation: Not stated.

Conflict of Interest: Not declared.


Singh N, Bhalla M, de Jager P, Gilca M. An Overview on Ashwagandha: A Rasayana (Rejuvenator) of Ayurveda. Afr J Tradit Complement Altern Med. 2011;8(Suppl 5):9. doi:10.4314/ajtcam.v8i5S.9

Publication Date: "2011"

Peer Reviewed: Yes

Study Design: Review study, "Comparative studies on the biological model of animals."

Methodology: Animal studies involving swimming endurance tests, adrenal gland analysis, gastric ulcer prevention, tumor inhibition tests, neurodegenerative disease models, and various biochemical assays.

Sample Size: Not explicitly mentioned. (review study)

Controls Used: Various, including "Control group of mice," "non-swimmer group," and "untreated animals."

Dose Used: Various, including "An aqueous suspension of Ashwagandha root was used at 100 mg/kg/oral dosage."

Statistical Significance Declared: Various, including "The results indicate a significant increase in the plasma corticosterone level, phagocytic index and avidity index in rats subjected to cold swimming stress."

Adverse Events due to Ashwagandha Supplementation: No adverse events directly linked to Ashwagandha supplementation were declared.

Conflict of Interest: No conflicts of interest declared.


Umadevi M, Rajeswari R, Rahale CS, Selvavenkadesh S, Pushpa R, Sampath Kumar KP, Bhowmik D. Traditional And Medicinal Uses of Withania Somnifera. The Pharma Innovation. 2012;1(9):102. ISSN: 2277-7695. CODEN Code: PIHNBQ. ZDB-Number: 2663038-2. IC Journal No: 7725.

Publication Date: "2012"

Peer Reviewed: Yes

Study Design: Not specified in the provided text.

Methodology: Not specified in the provided text.

Sample Size: Not specified in the provided text.

Controls Used: Not specified in the provided text.

Dose Used: Not specified in the provided text.

Statistical Significance Declared: Not specified in the provided text.

Adverse Events due to Ashwagandha Supplementation: "Excessive doses of ashwagandha have been reported to cause abortions, so pregnant women should avoid this herb." "Large doses can cause diarrhea, stomach upset and vomiting."

Conflict of Interest: Not specified in the provided text.


Yadav P, Lamba A, Meena A, Tanwar R, Choudhary A, Choudhary A, Choudhary W. An Overview on Health Benefits of Withania somnifera (Ashwagandha) in Veterinary Medicine. Curr J Appl Sci Technol. 2023;42(22):10-16. doi:10.9734/cjast/2023/v42i224166

Publication Date: "29/07/2023"

Peer Reviewed: Yes

Study Design: "Review Article"

Methodology: Analysis of various pharmacological effects of Withania somnifera based on previously conducted studies.

Sample Size: Not applicable (Review article)

Controls Used: Not applicable (Review article)

Dose Used: Various doses mentioned for different studies within the review, such as "500 mg/kg thrice in a week for 8 consecutive weeks."

Statistical Significance Declared: Not applicable (review article).

Adverse Events due to Ashwagandha Supplementation: None declared in the review.

Conflict of Interest: "Authors have declared that no competing interests exist."


Ng QX, Loke W, Foo NX, Tan WJ, Chan HW, Lim DY, Yeo WS. A systematic review of the clinical use of Withania somnifera (Ashwagandha) to ameliorate cognitive dysfunction. Phytother Res. 2020;34(3):583-590. doi:10.1002/ptr.6552

Publication Date: "19 November 2019"

Peer Reviewed: Yes

Study Design: "systematic review"

Methodology: Comprehensive search of databases (PubMed, EMBASE, Medline, PsycINFO, Clinicaltrials.gov), title/abstract screening, manual review, PRISMA guidelines, English-language articles, cross-checking for accuracy, Cochrane Collaboration's tool for assessing risk of bias.

Sample Size: "Five clinical studies"

Controls Used: "Randomized, placebo-controlled, double-blind"

Dose Used: Various, such as "Two teaspoons of BR-16A (Mentat) thrice daily for 12 weeks", "Two teaspoons of BR-16A (Mentat) thrice daily for 1 year", "W. somnifera capsule (Sensoril) 250–500 mg/day for 8 weeks", "W. somnifera (Sensoril) 250 mg/day for 14 days", "W. somnifera root extract (300 mg twice daily) for 8 weeks", "W. somnifera (Sensoril) 1,000 mg/day for 12 weeks"

Statistical Significance Declared: Various, such as "Statistically significant (p < .05) improvement in Wechsler Memory Scale III subtest scores for logical memory, as well as improved executive function, sustained attention, and information-processing speed."

Adverse Events due to Ashwagandha Supplementation: "No major adverse events were reported in any of the trials"

Conflict of Interest: "The authors report no conflicts of interest."


Kumar MS, Banmali D, Purnendu P, Bhuyan GC, Rao MM. Uses of Withania somnifera (Linn) Dunal (Ashwagandha) in Ayurveda and its Pharmacological Evidences. Research Journal of Pharmacology and Pharmacodynamics. 2016;8(1):23-29. doi:10.5958/2321-5836.2016.00006.9

Publication Date: "Accepted on 21.02.2016"

Peer Reviewed: Yes

Study Design: "review"

Methodology: Literature review of pharmacological studies on Ashwagandha.

Sample Size: Not applicable (review study).

Controls Used: Not applicable (review study).

Dose Used: Varies across studies reviewed; specific doses not provided.

Statistical Significance Declared: Not provided (review study).

Adverse Events due to Ashwagandha Supplementation: "Ashwagandha is not recommended in case of hyperthyroidism or pregnancy and can in high doses provoke certain intestinal problems." "In strong doses, Ashwagandha can have a hypnotic effect."

Conflict of Interest: Not declared in the provided text.


Sandhir R, Sood A. Neuroprotective Potential of Withania somnifera (Ashwagandha) in Neurological Conditions. In: Kaul SC, Wadhwa R, eds. Science of Ashwagandha: Preventive and Therapeutic Potentials. Cham: Springer International Publishing; 2017:373-387. doi:10.1007/978-3-319-59192-6_18

Publication Date: "First Online: 12 September 2017"

Peer Reviewed: Yes

Study Design: "Chapter"

Methodology: Animal models, cell cultures, behavioral tests, biochemical assays.

Sample Size: Various studies with different models (exact sample sizes not specified).

Controls Used: "Haloperidol", "Reserpine", "Kainate", "Pentylenetetrazol (PTZ)", "6-hydroxydopamine", "Middle cerebral artery occlusion (MCAO)".

Dose Used: "WS root extract (100 mg/kg)", "WS root extract (50 mg/kg)", "WS root extract (200 mg/kg)", "Withanolide A".

Statistical Significance Declared: Various p-values and significance levels reported in different studies, exact values not specified.

Adverse Events due to Ashwagandha Supplementation: No adverse events directly linked to Ashwagandha supplementation stated.

Conflict of Interest: None stated.


Bonilla DA, Moreno Y, Gho C, Petro JL, Odriozola-Martínez A, Kreider RB. Effects of Ashwagandha (Withania somnifera) on Physical Performance: Systematic Review and Bayesian Meta-Analysis.Journal of Functional Morphology and Kinesiology. 2021; 6(1):20. https://doi.org/10.3390/jfmk6010020

Publication Date: "11 February 2021"

Peer Reviewed: Yes

Study Design: "Systematic review and Bayesian meta-analysis"

Methodology: PRISMA-based comprehensive systematic review; Bayesian hierarchical models for subgroup meta-analysis; estimation statistics analysis.

Sample Size: "A total of 13 studies met the requirements of this systematic review, although only 12 were included in the quantitative analysis."

Controls Used: Not Applicable. (review study)

Dose Used: Not Applicable. (review study)

Statistical Significance Declared: "The Bayesian models showed that future interventions might be at least in some way beneficial on the analyzed outcomes considering the 95% credible intervals for the meta-analytic effect size."

Adverse Events due to Ashwagandha Supplementation: "None of the clinical trials have found serious adverse effects from the consumption of Ashwagandha in the doses and length administered."

Conflict of Interest: “D.A.B. serves as Science Product Manager for MTX Corporation® in Europe, a company that sells a dietary product with Ashwagandha, has acted as a scientific consultant for MET-Rx in Colombia and is a current scientific affiliate to the “Creatine in Health” scientific advisory board for AlzChem (Tostberg, GmbH). R.B.K. has conducted a number of industry-sponsored studies on sport nutrition-related nutrients that include Ashwagandha, has served as a paid consultant and received honorariums to speak at conferences by industry, and currently serves as chair of the “Creatine in Health” scientific advisory board for AlzChem. The other authors declare no conflicts of interest.”

What is Menopause?

Menopause is a natural biological process that marks the end of a woman's menstrual cycles. It is diagnosed after you've gone 12 consecutive months without a menstrual period. Menopause can happen in your 40s or 50s, with the average age in the United States being 51. It's a normal part of ageing, signifying the end of the reproductive years, similar to the way menstruation marks the start during puberty.

Biological Perspective

Menopause is not a disorder or a disease but a natural transition in a woman's life. Biologically, it occurs as a result of a decrease in the ovaries' production of the hormones oestrogen and progesterone, two hormones crucial for reproduction. This decline in hormone production causes changes in the menstrual cycle and eventually leads to its cessation.

  • Ovarian Ageing: As women age, the number and quality of eggs in the ovaries diminish, a process that accelerates in the mid to late 30s. By the time a woman reaches her late 40s or early 50s, the ovaries stop releasing eggs altogether, leading to the cessation of menstruation.
  • Hormonal Fluctuations: In the years leading up to menopause (perimenopause), hormonal production becomes more erratic. This can cause irregular menstrual cycles, which is often the first sign of approaching menopause.

The Role of Hormones in Triggering Menopause

The transition into menopause is primarily driven by changes in hormonal levels:

  • Oestrogen and Progesterone: These are the primary hormones that regulate the menstrual cycle. As menopause approaches, the levels of these hormones fluctuate and eventually decrease significantly.
  • FSH and LH: Follicle-stimulating hormone (FSH) and luteinizing hormone (LH) are produced by the pituitary gland. As the ovaries produce less oestrogen, levels of FSH and LH rise, which is often used as a marker to diagnose the onset of menopause.
  • Impact of Hormonal Changes: The decrease in oestrogen levels can affect many areas of the body, leading to symptoms like hot flashes, night sweats, mood changes, and changes in sexual function. The long-term effects of reduced oestrogen production include an increased risk of osteoporosis and heart disease.

Understanding menopause from a biological standpoint helps demystify the process and sets the stage for exploring how to manage and thrive during this natural transition in life.



Stages of Menopause

Perimenopause: Early Signs and Symptoms

  • Definition: Perimenopause, also known as the menopausal transition, is the period leading up to menopause. It can start several years before menopause, typically in a woman's 40s, but may begin as early as the 30s.
  • Hormonal Changes: During perimenopause, the ovaries gradually produce less oestrogen, leading to changes in the menstrual cycle and the onset of menopause-related symptoms.
  • Symptoms: Common symptoms include irregular periods, hot flashes, sleep disturbances, mood swings, and changes in sexual function. The duration and severity of these symptoms can vary greatly.
  • Duration: Perimenopause typically lasts around four years but can range from a few months to a decade.

Menopause: Identifying the Transition

  • Definition: Menopause is officially reached when a woman has not had a menstrual period for 12 consecutive months. It marks the end of the reproductive years.
  • Hormonal Shift: By this stage, the ovaries have significantly reduced oestrogen production. The body adjusts to this new hormonal environment.
  • Symptoms: While some symptoms may continue, they often become less intense over time. This stage is a key transition point, marking the end of the perimenopausal period.

Postmenopause: Life After Menopause

  • Definition: Postmenopause is the stage following menopause, encompassing the rest of a woman's life beyond her reproductive years.
  • Physical Changes: The body continues to adjust to lower levels of oestrogen. Some symptoms of menopause may subside, but new health considerations arise.
  • Long-Term Health: Postmenopausal women are at a higher risk for certain health conditions like osteoporosis and heart disease due to decreased oestrogen levels. It's important to focus on long-term health strategies, including diet, exercise, and regular health screenings.
  • Lifestyle Adjustments: This period can be a time of significant personal growth and development. Many women find new interests, hobbies, and ways to focus on their health and wellbeing.

Understanding the stages of menopause helps in recognizing and normalising the experiences and changes that occur during this transition. It provides a framework for managing symptoms effectively and planning for long-term health and wellness post-menopause.



Symptoms of Menopause

Common Physical Symptoms

  • Hot Flashes: Sudden feelings of heat in the upper body, which can be mild or intense enough to disrupt daily activities. They may be accompanied by redness of the skin and sweating.
  • Sleep Disturbances: Difficulty sleeping, night sweats, and waking up frequently during the night are common. These issues can lead to daytime tiredness and fatigue.
  • Vaginal and Urinary Changes: Decreased oestrogen levels can lead to vaginal dryness, discomfort during intercourse, and urinary problems like urgency or recurrent infections.
  • Other Symptoms: Women may also experience joint pain, headaches, palpitations, and changes in hair and skin texture.

Emotional and Cognitive Changes

  • Mood Swings: Fluctuating hormone levels can cause emotional changes such as mood swings, irritability, and increased susceptibility to stress and anxiety.
  • Memory and Concentration: Some women report short-term memory problems and difficulty concentrating, often referred to as "menopausal fog."
  • Depression and Anxiety: The menopausal transition can increase the risk of depression and anxiety, not solely due to hormonal changes but also influenced by sleep disturbances, stress, and changing life circumstances.

Long-Term Health Considerations

  • Bone Density: Post-menopausal women are at an increased risk for osteoporosis due to lower oestrogen levels, which affect bone density.
  • Cardiovascular Health: The risk of heart disease rises after menopause, partly due to increasing age, but also due to changes in blood pressure, cholesterol levels, and body fat distribution.
  • Weight Gain: Metabolism slows down during menopause, making it easier to gain weight, particularly around the abdomen.
  • Preventive Health Measures: Regular health screenings, such as mammograms, bone density tests, and cardiovascular check-ups, become increasingly important during and after menopause.

Understanding these symptoms and long-term health considerations is crucial in effectively managing the menopause transition. It’s important to recognize that experiences vary widely among women, and what’s normal for one may not be for another. This awareness allows for a more personalised approach to managing menopause, focusing on individual needs and symptoms.

 

Menopause Myths and Facts

Addressing Common Myths About Menopause

Myth: Menopause always starts at age 50
    • Fact: The onset of menopause varies. While the average age is around 51, it can occur in the 40s or later in the 50s. Early or premature menopause (before 40) is also possible but less common.
Myth: Menopause symptoms are always severe
    • Fact: Symptom severity varies. Some women experience intense symptoms, while others have mild or no symptoms. Lifestyle, genetics, and overall health play a role in symptom intensity.
Myth: You can’t get pregnant during perimenopause
    • Fact: Pregnancy is still possible during perimenopause because ovulation can be unpredictable. Effective contraception is recommended until menopause is confirmed (one year without periods).

Separating Fact from Fiction with Scientific Evidence

Fiction: Menopause marks the end of a woman's sexuality
    • Evidence-Based Fact: Many women enjoy a fulfilling sex life after menopause. While hormonal changes can affect libido and comfort, treatments and lifestyle adjustments can effectively address these issues.
Fiction: Hormone replacement therapy (HRT) is unsafe for all women
    • Evidence-Based Fact: HRT can be a safe and effective treatment for many women to manage menopausal symptoms. The benefits and risks of HRT vary depending on individual health factors and should be discussed with a healthcare provider.

 

How Menopause Affects Women Differently

  • Individual Variability: Menopause is a highly individual experience. Factors such as cultural background, lifestyle, overall health, and personal attitudes towards ageing can influence how a woman experiences menopause.
  • Diverse Symptoms: The type and severity of symptoms differ significantly among women. While some may struggle with hot flashes and emotional changes, others may have different or fewer symptoms.
  • Impact on Daily Life: The effect of menopause on daily life and well-being also varies. Some women may find menopause to be a challenging period requiring significant lifestyle adjustments, while others may experience it as a time of liberation and renewed energy.

By debunking common myths and understanding the facts about menopause, women can approach this life stage with more confidence and less apprehension. Recognizing the individual nature of menopause encourages a more personalised approach to managing its symptoms and impacts. This knowledge empowers women to make informed decisions about their health and well-being during the menopausal transition.

We’ve laid the groundwork for understanding menopause. With this knowledge, you'll be better prepared to explore the upcoming modules, which focus on managing symptoms and enhancing your quality of life during this transition.

Back to blog